School of Medicine

Wayne State University School of Medicine

Funded Research

Total research funding for the Neurology department was more than $2.5 million for the year.  This does not include research funds for Pediatric Neurology, which are administered through the Department of Pediatrics or Neuropathology, a division of Pathology.

The department is nationally recognized for its biomedical research. Sources of funding include the federal government (National Institutes of Health, National Science Foundation, and Veterans Administration), voluntary health organizations and foundations, including the National Multiple Sclerosis Society, Muscular Dystrophy Society, American Heart Association, Charcot-Marie-Tooth Foundation, Blue Cross/Blue Shield of Michigan, as well as pharmaceutical corporations.

 

“Effect of Nuedexta on central neuropathic pain: A randomized, multiple center, double-blind, placebo-controlled study in multiple sclerosis.” Sponsor: Avanir. Evanthia Bernitsas, PI, Omar Khan, Co-PI

 “A Phase III, multicenter, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis.” Sponsor: Roche.  Evanthia Bernitsas, PI, Omar Khan, Co-PI

“Multimodal In-Vivo Non-conventional Brain MRI Investigation into Myelin Tissue Injury in Patients with Alzheimer’s Disease.” Sponsor: Albert and Goldye Nelson Research Foundation. Pratik Bhattacharya, PI, Omar Khan, co-PI.

“Children with Epilepsy in Developing Countries.” Sponsor: NIH. Harry Chugani, PI.

“Loss of Metabolic Homeostasis in the Brain of Patients with Multiple Sclerosis.” Sponsor: FCMSC/BAYER. Paula Dore-Duffy, PI.

“Flex: An Open-Label, Non-Inferiority Study Evaluating the Efficacy and Safety of Two Injection Schedules of Xeomin (incobotulinumtoxin A) [Short Flex vs Long Flex] in Subjects with Cervical Dystonia with< 10 Weeks of Benefit from OnabotulinumtoxinA Treatment.” Sponsor: Merz Pharmaceuticals. Edwin George, PI.

“Developing a Mouse Model of Sensory and Cognitive Deficits for Multiple Sclerosis.” Sponsor: U.S. Army Medical Research and Material Command. Alexander Gow, PI.

“Trb3-mediated Modulation of Oligodendrocyte stress.” Sponsor: NIH, NINDS. Alexander Gow, PI.

 “Modulation of EAE with Infared Light.” Sponsor: National Multiple Sclerosis Society. John Kamholz, PI, Fei Song, co-PI.

“Data Entry for Patients with Lysosomal Storage Disease.” Sponsor: Genzyme, Inc. John Kamholz, Pi.

“A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Patients with Relapsing-Remitting Multiple Sclerosis (CombiRx-Phase III)” Sponsor: NINDS (NIH) NS. Omar Khan, PI.

 “To examine the effect of Natalizumab on Tissue Injury and  Repair in the Central Nervous System: a Two-Year Novel Multi-Parametric MRI Exploratory study” Sponsor: Biogen Idec. Omar Khan, PI
 
“Effect of rasagiline (Azilect) on tissue injury in patients with Parkinson’s Disease: An Exploratory non-conventional multi-modal MRI study” Sponsor: Teva Neuroscience. Omar Khan, PI
 
“MR Image Analysis Sub-study of a Multi-Center Long-term Study of Patients with Relapsing-Remitting Multiple Sclerosis Treated with Copaxone for 20 years.” Sponsot: Teva Pharmaceuticals. Omar Khan, PI
 
“A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active-Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon β-1a) to Natalizumab in Subjects with Relapsing‑Remitting Multiple Sclerosis (Surpass Study)” Sponsor: Biogen Idec. Omar Khan, PI
 
“Glatiramer Acetate Low-Frequency Adminitrsation (GALA) study A phase III randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of glatiramer acetate 40 mg subcutaneously three times a week compared to placebo in relapsing-remitting multiple sclerosis.” Sponsor: Teva Pharmaeuticals. Omar Khan, PI
 
“A Phase 3 Extension Study of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif) in Patients with Relapsing-Remitting Multiple Sclerosis Who Have Completed Core Phase III (MS CARE I and II) and CAMMS 223 studies” Sponsor: Genzyme. Omar Khan, PI
 
“Extension study to evaluate the efficacy and safety of teriflunomide (HMR1726D) in reducing the frequency of relapses and delaying the accumulation of physical disability in subjects with multiple sclerosis with relapses” Sponsor: Sanofi-Aventis. Omar Khan, PI
 
“Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Two Doses of Oral Dalfampridine Extended Release Tablets (5 mg and 10 mg twice daily) in Patients with Multiple Sclerosis.” Sponsor: Acorda Therapeutics. Omar Khan, PI
 
"A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg administered orally once daily with glatiramer acteate 20 mg administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis.” Sponsor: Novartis.  Omar Khan, PI

 “To examine the effect of fingolimod on Tissue Injury and Repair in the Central Nervous System: a Two-Year Novel Multi-Parametric MRI Exploratory study in Patients with Relapsing Multiple Sclerosis” Sponsor:  Novartis Pharmaceuticals. Omar Khan, PI

 “A Phase I, multicenter, randomized, double-blind, placebo-controlled, ascending single-dose study of the safety, tolerability, and pharmacokinetics of intravenous VX15/2503 in patients with multiple sclerosis” Sponsor: Vaccinex Inc. Omar Khan, PI

 “A double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg FTY720 administered orally once daily versus placebo in patients with primary progressive multiple sclerosis.” Sponsor: Novartis. Omar Khan, PI

“A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient Outcomes, Safety and Tolerability of Fingolimod (FTY720) 0.5mg/day in Patients with Relapsing Forms of Multiple Sclerosis who are Candidates for MS Therapy Change From Previous Disease Modifying Therapy (EPOC). Sponsor: Novartis Pharmaceuticals. Omar Khan, PI.

 “A Randomized Double Blind Double-Dummy Parallel Group Study to Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Inteferon Beta-1a (RebifA) in Patients with RRMS.” Sponsor: Genentech, Inc. Omar Khan, PI.

“The Effect of Dextromethorphan (DM) on Glial Cell Function: Proliferation, Differentiation, Protection and Responses to Cytokines.” Sponsor: Avanir Pharmaceuticals. Robert Lisak, PI, Joyce Benjamins, co PI.

“Effect of ACTH on Glial Cell Function Proliferation and Effects of Cytokines on Gene Regulation.” Sponsor: Questcor Pharmaceuticals, Inc. Robert Lisak, PI, Joyce Benjamins, co-PI.

“A Randomized Double-Blind Parallel Group Placebo-Controlled Study to Evaluate the Efficacy and Safety of Desmoteplase in Acute Ischemic Stroke.’ Sponsor: Lundbeck. Kumar Rajamani, PI.

“Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects with Partial Epilepsy Not Well Controlled by Current Antiepileptic Drug.” Sponsor: Sunovion Pharmaceuticals, Inc. Aashit Shah, PI.

“Electrical, Molecular and Clinical Correlates of Human Interictal Spiking.” Sponsor: National Institute of Neurological Disorders and Stroke. Aashit Shah, PI.

“Correlation of Plasma and Cerebrospinal Fluid (CSF) Levels of Lacrosamise (LCM).” Sponsor: UCB Pharma. Aashit Shah, PI.

“A Randomized Double Blind Placebo Controlled Study of the Safety and Efficacy of Intranasal Midazolam (USL 261) in the Outpatient Treatment of Subjects with Seizure Clusters.’ Sponsor: Pharmanet, Inc. Aashit Shah, PI.

“USP25 Regulates Cellular Levels of Alzheimer’s Disease-causing-b-Amyloid Precursor Protein.” Sponsor: Albert and Goldye Nelson Research Foundation.  Sokol Todi, PI.

“Mechanisms of Polyglutamine Neurodegeneration.” Sponsor: NINDS.  Henry Paulson, PI, Sokol Todi, co-PI.

“An Exploratory, Non-Conventional, Advanced MRI Study to Examine the Neuroprotective Effect of Azilect Added to Copaxone in Patients with RRMS.” Sponsor: Teva Pharmaceuticals, Ltd. Alexandros Tselis, PI, Omar Khan, co-PI.

“JCV Antibody Program in Patients with Relapsing Multiple Sclerosis STRATIFY 2.” Sponsor: Biogen, Inc. Alexandros Tselis, PI, Omar Khan, co-PI.

In addition there are many ongoing grants and clinical trials underway.  The funding for these began prior to 2011.